Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel Testing Method Detects HIV and Hepatitis B/C from Single Drop of Blood

By LabMedica International staff writers
Posted on 14 Apr 2023

Every year, over one million people succumb to hepatitis B or hepatitis C, while 650,000 die from HIV-related causes and 1. More...

5 million contract HIV. The World Health Organization aims to eliminate all three viruses by 2030, requiring new testing methods to decrease case numbers. The most common test for hepatitis B, hepatitis C, and HIV involves drawing blood from a vein with a needle. However, this approach is not always suitable in prisons, drug rehabilitation centers, and homeless shelters or in countries where blood sample shipping and refrigerated storage pose challenges. Alternative methods, such as dried blood spot tests, can detect nucleic acid from the three viruses in a single blood spot.

At this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, (April 15–18), researchers at Copenhagen University Hospital (Copenhagen, Denmark) presented data on a test capable of detecting HIV, hepatitis B, and hepatitis C using a single drop of blood. The test involves pricking the individual's finger, collecting a few blood spots on filter paper, and allowing them to dry. The Hologic Panther System, commonly found in public health laboratories, then employs transcription mediated amplification to analyze one blood spot for genetic material from the three viruses.

The researchers assessed the test by analyzing 20 samples containing known amounts of HIV, hepatitis B, and hepatitis C using the dried blood spot method (60 samples in total) and successfully detected the viruses in all samples. Plasma dilution determined the lower detection limit, revealing the capability to detect the viruses at levels significantly lower than those typically found in untreated patients.

“We've shown that using existing hospital equipment, it is possible to detect HIV, hepatitis B and hepatitis C from a single drop of blood,” said Stephen Nilsson-Møller at the Department of Clinical Microbiology, Copenhagen University Hospital. “The dried blood spot test is ideal for places where you don't want to use a needle for safety reasons or where it is less practical. It is also suitable for developing countries or places where you run the risk of a blood sample being ruined before it is transferred to a laboratory that can analyze it. Blood samples need to be analyzed within six hours when kept at room temperature, while dried blood spots can last for nine months without refrigeration.”

Related Links:
Copenhagen University Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Thyroid Test
Anti-Thyroid EIA Test
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.